Alexander Dechêne

Alexander Dechêne

Auto-generated profile, based on publicly available information

Alexander Dechêne

Department for Internal Medicine, Nuremberg Hospital North, Paracelsus Private Medical University Nuremberg, Nuremberg, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2014 in Digestion
Verified
Journal Article
Closed access
PDF file
ADAlexander Dechêne
Alexander Dechêne
JSJan-Peter Sowa
Jan-Peter Sowa
MSMartin Schlattjan
Martin Schlattjan
AWAlexander Wree
Alexander Wree
SBSandra Blomeyer
Sandra Blomeyer
ACAli Canbay
Ali Canbay
Background/Aims: For diagnosis, prognosis, and treatment of acute liver failure (ALF), macroscopic evaluation and histological assessment of the liver are important. Due to impaired coagulation in ALF, the risk of bleeding is high after a percutaneous liver biopsy. Our aims were to assess (i) safety and benefit of mini laparoscopy (ML) in patients with ALF and (ii) the potential utility of histological markers in ALF prognosis. Methods: ML was performed in 39 patients with ALF to assess liver surface and to obtain a liver biopsy. Serological markers of liver injury and immunohistochemical detection of cell death and proliferation were compared to a non-ALF group (n = 10). Results: Liver biopsies were successfully performed in all patients with no significant complications. All patients had markedly elevated M30 and M65 levels in the serum. In the liver, M30 and Ki67 immune-reactive cells were more abundant in those with ALF. Importantly, there were significantly more Ki67-positive cells but fewer M30-positive cells in livers of ALF patients who recovered spontaneously. Conclusion: ML with liver biopsy in patients with ALF and severe coagulopathy is safe. Immunohistochemical detection of liver cell death and regeneration may identify individuals who would recover spontaneously or who would need a liver transplant.

4 February 2015 in Digestive Endoscopy
Verified
Journal Article
Closed access
PDF file
ADAlexander Dechêne
Alexander Dechêne
CKCathrin Kodde
Cathrin Kodde
SKSimone Kathemann
Simone Kathemann
JTJürgen Treckmann
Jürgen Treckmann
ELElke Lainka
Elke Lainka
ACAli Canbay
Ali Canbay

6 August 2009 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
JBJan Best
Jan Best
ADA. Dechene
A. Dechene
SES. Esser
S. Esser
GGG. Gerken
G. Gerken
ACAli Canbay
Ali Canbay
Eine im 2. Trimenon schwangere 33-jährige Patientin (15. SSW) mit einer seit Geburt des 1. Kindes bekannten Colitis ulcerosa stellte sich in unserer Klinik aufgrund von neu aufgetretenem, progredientem Gewichtsverlust, Fieber, Leukozytose und blutig/schleimig tingierten Diarrhöen vor. Endoskopisch konnte ein akuter Schub der bekannten Colitis ulcerosa nachgewiesen werden. Wenige Tage später manifestierten sich zusätzlich kutane erythematöse Knötchen und Plaques, anhand von Hautbiopsien wurde die klinische Verdachtsdiagnose einer neutrophilen Dermatitis (Sweet-Syndrom) histologisch gesichert. Eine unverzüglich initiierte, hoch dosierte intravenöse Steroidstoßtherapie erzielte eine unmittelbare Remission, sowohl der kutanen als auch der intestinalen Manifestationen. Beide Krankheitsentitäten weisen eng miteinander assoziierte immunologische Alterationen auf. Pathogenetisch bestehen sowohl bei den Aktivierungsmustern auf Zytokin- und Chemokinebene als auch bei der Aktivierung inflammatorischer Zellreihen signifikante Parallelen. Aktuelle Daten belegen, dass es im Rahmen der Gravidität zu einer Elevation proinflammatorischer Zytokinspiegel kommen kann. Dieses Phänomen spielt möglicherweise eine Schlüsselrolle, sowohl bei der Manifestation intestinaler und extraintestinaler Symptome als auch für den Schweregrad des Krankheitsverlaufs. Im Folgenden werden ein Diagnostikalgorithmus und ein pathogenetischer Erklärungsansatz für das Sweet-Syndrom diskutiert. A 33-year old pregnant patient (pregnancy week 15) with a past medical history of ulcerative colitis with onset of the disease following the birth of her first child was admitted to the hospital with symptoms of weight loss, pyrexia, leukocytosis and bloody and mucous diarrhoea. Total ileocolonoscopy revealed an acute flare of ulcerative colitis. Within a few days, tender erythematous skin lesions occurred and were histologically proven to be neutrophilic dermatosis. Treatment with highly-dosed prednisone led to a complete remission of both cutaneous and intestinal manifestations. Both pathogenic entities are associated with similar immunological alterations, such as comparable cytokine and chemokine release patterns and recruitment of inflammatory cells. Recent data also indicates that proinflammatory cytokine levels are elevated in pregnancy, which might be pivotal in the pathogenesis and the severity of intestinal and extraintestinal symptoms. We present and discuss a diagnostic algorithm and an overall therapeutic rationale for Sweet’s syndrome.

1 June 2018 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
MWMarcel Wiesweg
Marcel Wiesweg
Henning ReisHenning Reis
Henning Reis
TKTobias Köster
Tobias Köster
MGMoritz Goetz
Moritz Goetz
KWKarl Worm
Karl Worm
SKStefan Kasper
Stefan Kasper

21 March 2022 in Journal of Clinical and Translational Hepatology
Verified
Journal Article
Open access
MJMichael Jahn
Michael Jahn
MÖMustafa Özcürümez
Mustafa Özcürümez
Sebastian DolffSebastian Dolff
Sebastian Dolff
HRHana Rohn
Hana Rohn
Dominik HeiderDominik Heider
Dominik Heider
AKAntonios Katsounas
Antonios Katsounas
Polymerase chain reaction (PCR) techniques provide rapid detection of pathogens. This pilot study evaluated the diagnostic utility and clinical impact of multiplex real-time PCR (mRT-PCR, SeptiFast) vs. conventional microbial culture (CMC) in bile samples of patients with chronic cholestatic liver diseases (cCLDs), endoscopic retrograde cholangio-pancreatography (ERCP), and peri-interventional-antimicrobial-prophylaxis (pAP).

20 May 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKStefan Kasper
Stefan Kasper
JMJohannes Meiler
Johannes Meiler
HKHeike Knipp
Heike Knipp
THThomas Hoehler
Thomas Hoehler
PRPeter Reimer
Peter Reimer
TTTanja Trarbach
Tanja Trarbach
3568 Background: The multicenter, single-arm, phase II CEBIFOX trial (Simon`s two stage minimax design) evaluated the efficacy of mFOLFOX6 + biweekly cetuximab (500 mg/m2) as 1st line therapy in KRAS wt (exon 2) mCRC. Final efficacy data as well as extended molecular and clinical subgroup analyses are presented. Methods: Primary endpoint was objective response rate (ORR) per RECIST 1.0, secondary endpoints were safety, metastasectomy rate, quality of life, progression-free (PFS) and overall survival (OS). Extended molecular profiling was performed using NGS-based panel sequencing including NRAS (exon 2-4), KRAS (exon 2-4), BRAF (exon 15) and PI3KCA (exon 10 and 21). Clinical parameters included: tumor localisation (right sided vs. left sided-LCRC), liver-limited disease (LLD), early tumor-shrinkage (ETS), depth of response (DPR), metastasectomy and inflammation markers (neutrophil/lymphocyte ratio-NLR). Differences in ORR, PFS and OS were calculated for subgroups using chi-square and logrank tests. Hazard...